Aloe-emodin exerts a potent anticancer and immunomodulatory activity on BRAF-mutated human melanoma cells

European Journal of Pharmacology

Volumn 762, Issue , 2015, Pages 283-292

  Tabolacci, Claudio ^a,b   Cordella, Martina ^a   Turcano, Lorenzo ^b   Rossi, Stefania ^a   Lentini, Alessandro ^b   Mariotti, Sabrina ^a   Nisini, Roberto ^a   Sette, Giovanni ^c   Eramo, Adriana ^a   Piredda, Lucia ^b   De Maria, Ruggero ^c   Facchiano, Francesco ^a   Beninati, Simone ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Aloe emodin; BRAF mutation; Cytokines; Melanoma cell differentiation; Melanoma initiating cells

Indexed keywords

ALOE EMODIN; ANTHRAQUINONE DERIVATIVE; B RAF KINASE; CHEMOKINE; CISPLATIN; CYTOKINE; DABRAFENIB; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYANTHRAQUINONE; METHOTREXATE; MUTANT PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR; OXIME;

A375 CELL LINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CELL ADHESION ASSAY; CELL DIFFERENTIATION; CELL INVASION ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOMODULATORY ACTIVITY; IN VITRO STUDY; MELANOMA CELL; MELANOMA CELL LINE; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; APOPTOSIS; CELL ADHESION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; MELANOMA; METASTASIS; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; IMIDAZOLES; IMMUNOLOGIC FACTORS; MELANOMA; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84931281574     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.05.057     Document Type: Article

References (64)

1. G. Alatrash, H. Jakher, P.D. Stafford, and E.A. Mittendorf Cancer immunotherapies, their safety and toxicity Expert Opin. Drug Saf. 12 2013 631 645
2. S. Balachandran, and G.P. Adams Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective J. Interferon. Cytokine Res. 33 2013 171 180
3. R.N. Barnes, P.J. Bungay, B.M. Elliott, P.L. Walton, and M. Griffin Alterations in the distribution and activity of transglutaminase during tumor-growth and metastasis Carcinogenesis 6 1985 459 463
4. S. Bartolini, A. Mai, M. Artico, N. Paesano, D. Rotili, C. Spadafora, and G. Sbardella 6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase J. Med. Chem. 48 2005 6776 6778
5. L. Berglund, E. Bjorling, and P. Oksvold A genecentric human protein atlas for expression profiles based on antibodies Mol. Cell. Proteomics 710 2008 2019 2027
6. T. Blankenstein, P.G. Coulie, E. Gilboa, and E.M. Jaffee The determinants of tumour immunogenicity Nat. Rev. Cancer 12 2012 307 313
7. A. Budillon, C. Carbone, and E. Di Gennaro Tissue transglutaminase: a new target to reverse cancer drug resistance Amino Acids 44 2013 63 72
8. E.R. Cantwell-Dorris, J.J. O'Leary, and O.M. Sheils BRAFV600E: implications for carcinogenesis and molecular therapy Mol. Cancer Ther 10 2011 385 394
9. J. Chen, Y. Li, T.S. Yu, R.M. McKay, D.K. Burns, S.G. Kernie, and L.F. Parada A restricted cell population propagates glioblastoma growth after chemotherapy Nature 488 2012 522 526
10. K.G. Chen, R.D. Leapman, G. Zhang, B. Lai, J.C. Valencia, C.O. Cardarelli, W.D. Vieira, V.J. Hearing, and M.M. Gottesman Influence of melanosome dynamics on melanoma drug sensitivity J. Natl. Cancer Inst. 101 2009 1259 1271
11. P. Chen, C. Li, X. Li, J. Li, R. Chu, and H. Wang Higher dietary folate intake reduces the breast cancer risk: a systematic review and meta-analysis Br. J. Cancer 110 2014 2327 2338
12. C. Cocco, V. Pistoia, and I. Airoldi New perspectives for melanoma immunotherapy role of IL-12 Curr. Mol. Med. 9 2009 459 469
13. M. Cojoc, K. Mäbert, M.H. Muders, and A. Dubrovska A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms Semin. Cancer Biol. 31 2015 16 27
14. M.P. Colombo, and G. Trinchieri Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine Growth Factor Rev. 13 2002 155 168
15. F.D. Cruz, and I. Matushansky Solid tumor differentiation therapy - is it possible? Oncotarget 3 2012 559 567
16. A. Eramo, T.L. Haas, and R. De Maria Lung cancer stem cells: tools and targets to fight lung cancer Oncogene 29 2010 4625 4635
17. A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio, C. Conticello, L. Ruco, C. Peschle, and R. De Maria Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death Differ. 15 2008 504 514
18. F. Facchiano, D. D'Arcangelo, A. Lentini, S. Rossi, C. Senatore, T. Pannellini, C. Tabolacci, A.M. Facchiano, A. Facchiano, and S. Beninati Tissue transglutaminase activity protects from cutaneous melanoma metastatic dissemination: an in vivo study Amino Acids 44 2013 53 61
19. F. Facchiano, D. D'Arcangelo, A. Riccomi, A. Lentini, S. Beninati, and M.C. Capogrossi Transglutaminase activity is involved in polyamine-induced programmed cell death Exp. Cell Res. 271 2001 118 129
20. L. Falasca, V. Iadevaia, F. Ciccosanti, G. Melino, A. Serafino, and M. Piacentini Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment J. Immunol. 174 2005 7330 7340
21. M.P. Fuggetta, S. D'Atri, G. Lanzilli, M. Tricarico, E. Cannavò, G. Zambruno, R. Falchetti, and G. Ravagnan In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide Melanoma Res. 14 2004 189 196
22. G.T. Gibney, and J.S. Zager Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies Expert Opin. Drug Metab. Toxicol. 9 2013 893 899
23. T.E. Grotz, L. Kottschade, E.S. Pavey, S.N. Markovic, and J.W. Jakub Adjuvant GM-CSF improves survival in high-risk stage IIIC melanoma: a single-center study Am. J. Clin. Oncol. 37 2014 467 472
24. J.M. Guo, B.X. Xiao, Q. Liu, S. Zhang, D.H. Liu, and Z.H. Gong Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation Acta Pharmacol. Sin. 28 2007 1991 1995
25. E. Harlev, E. Nevo, E.P. Lansky, R. Ofir, and A. Bishayee Anticancer potential of aloes: antioxidant, antiproliferative, and immunostimulatory attributes Planta Med. 78 2012 843 852
26. C. Holohan, S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston Cancer drug resistance: an evolving paradigm Nat. Rev. Cancer 13 2013 714 726
27. P.H. Huang, C.Y. Huang, M.C. Chen, Y.T. Lee, C.H. Yue, H.Y. Wang, and H. Lin Emodin and aloe-emodin suppress breast cancer cell proliferation through ER α inhibition Evid. Based Complement. Altern. Med. 2013 2013 376123
28. Q. Huang, G. Lu, H.M. Shen, M.C. Chung, and C.N. Ong Anti-cancer properties of anthraquinones from Rhubarb Med. Res. Rev. 27 2007 609 630
29. D. Ickowicz Schwartz, Y. Gozlan, L. Greenbaum, T. Babushkina, D.J. Katcoff, and Z. Malik Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma Br. J. Cancer 90 2004 833 841
30. R. Kolb, G.H. Liu, A.M. Janowski, F.S. Sutterwala, and W. Zhang Inflammasomes in cancer: a double-edged sword Protein Cell 5 2014 12 20
31. M.Y. Lai, M.J. Hour, H. Wing-Cheung Leung, W.H. Yang, and H.Z. Lee Chaperones are the target in aloe-emodin-induced human lung nonsmall carcinoma H460 cell apoptosis Eur. J. Pharmacol. 573 2007 1 10
32. E. Lázár-Molnár, H. Hegyesi, S. Tóth, and A. Falus Autocrine and paracrine regulation by cytokines and growth factors in melanoma Cytokine 12 2000 547 554
33. J. Li, P. Liu, H. Mao, A. Wanga, and X. Zhang Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro Oncol. Rep. 21 2009 1605 1610
34. R. Lotan, and D. Lotan Stimulation of melanogenesis in a human melanoma cell by retinoids Cancer Res. 40 1980 3345 3350
35. I. Matic, A. Sacchi, A. Rinaldi, G. Melino, C. Khosla, L. Falasca, and M. Piacentini Characterization of transglutaminase type II role in dendritic cell differentiation and function J. Leukoc. Biol. 88 2010 181 188
36. A. Miguel, M.J. Herrero, L. Sendra, R. Botella, R. Algás, M. Sánchez, and S.F. Aliño Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines Cancer Gene Ther. 20 2013 576 581
37. M.V. Nurminskaya, and A.M. Belkin Cellular functions of tissue transglutaminase Int. Rev. Cell Mol. Biol. 294 2012 1 97
38. V. Orian-Rousseau CD44, a therapeutic target for metastasising tumours Eur. J. Cancer 46 2010 1271 1277
39. B. Ozpolat, G. Lopez-Berestein, and K. Mehta ATRA(ouble) in the treatment of acute promyelocytic leukemia J. Biol. Regul. Homeost. Agents 15 2001 107 122
40. H.C. Pal, S. Sharma, L.R. Strickland, S.K. Katiyar, M.E. Ballestas, M. Athar, C.A. Elmets, and F. Afaq Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways PLoS One 9 2014 e86338
41. J. Radovic, D. Maksimovic-Ivanic, G. Timotijevic, S. Popadic, Z. Ramic, V. Trajkovic, D. Miljkovic, S. Stosic-Grujicic, and S. Mijatovic Cell-type dependent response of melanoma cells to aloe emodin Food Chem. Toxicol. 50 2012 3181 3189
42. T. Regad Molecular and cellular pathogenesis of melanoma initiation and progression Cell. Mol. Life Sci. 70 2013 4055 4065
43. G. Sette, K. Fecchi, V. Salvati, F. Lotti, E. Pilozzi, E. Duranti, M. Biffoni, A. Pagliuca, D. Martinetti, L. Memeo, M. Milella, R. De Maria, and A. Eramo Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts J. Exp. Clin. Cancer Res. 32 2013 91
44. H.M. Shaw, and P.D. Nathan Vemurafenib in melanoma Expert Rev. Anticancer Ther. 13 2013 513 522
45. A. Shimanovsky, A. Jethava, and C.A. Dasanu Immune alterations in malignant melanoma and current immunotherapy concepts Expert Opin. Biol. Ther. 13 2013 1413 1427
46. S. Sivendran, R. Chang, L. Pham, and R.G. Phelps Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease J. Investig. Dermatol. 134 2014 2202 2211
47. A. Skladanowski, and J. Konopa Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells Biochem. Pharmacol. 46 1993 375 382
48. G. Sonpavde, and T.K. Choueiri Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma Br. J. Cancer 107 2012 1009 1016
49. P.A. Sotiropoulou, M.S. Christodoulou, A. Silvani, C. Herold-Mende, and D. Passarella Chemical approaches to targeting drug resistance in cancer stem cells Drug Discov. Today 19 2014 1547 1562
50. C. Tabolacci, A. Lentini, P. Mattioli, B. Provenzano, S. Oliverio, F. Carlomosti, and S. Beninati Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells Life Sci. 87 2010 316 324
51. C. Tabolacci, A. Lentini, B. Provenzano, and S. Beninati Evidences for a role of protein cross-links in transglutaminase-related disease Amino Acids 42 2012 975 986
52. C. Tabolacci, S. Oliverio, A. Lentini, S. Rossi, A. Galbiati, C. Montesano, P. Mattioli, B. Provenzano, F. Facchiano, and S. Beninati Aloe-emodin as antiproliferative and differentiating agent on human U937 monoblastic leukemia cells Life Sci. 89 2011 812 820
53. H.A. Tawbi, and S.C. Buch Chemotherapy resistance abrogation in metastatic melanoma Clin. Adv. Hematol. Oncol. 8 2010 259 266
54. L. Tentori, P.M. Lacal, and G. Graziani Challenging resistance mechanisms to therapies for metastatic melanoma Trends Pharmacol. Sci. 34 2013 656 666
55. T. Thangasamy, S. Sittadjody, G.C. Mitchell, E.E. Mendoza, V.M. Radhakrishnan, K.H. Limesand, and R. Burd Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73 BMC Cancer 10 2010 282
56. M. Todaro, M. Gaggianesi, V. Catalano, A. Benfante, F. Iovino, M. Biffoni, T. Apuzzo, I. Sperduti, S. Volpe, G. Cocorullo, G. Gulotta, F. Dieli, R. De Maria, and G. Stassi CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis Cell Stem Cell 14 2014 342 356
57. V.A. Trinh, J.E. Davis, J.E. Anderson, and K.B. Kim Dabrafenib therapy for advanced melanoma Ann. Pharmacother. 48 2014 519 529
58. M. Uhlén, E. Björling, and C. Agaton A human protein atlas for normal and cancer tissues based on antibody proteomics Mol. Cell. Proteomics 412 2005 1920 1932
59. A. Verma, and K. Mehta Tissue transglutaminase-mediated chemoresistance in cancer cells Drug Resist. Updat. 10 2007 144 151
60. J. Weber Immunotherapy for melanoma Curr. Opin. Oncol. 23 2011 163 169
61. J.S. Wilmott, L.E. Haydu, A.M. Menzies, T. Lum, J. Hyman, J.F. Thompson, P. Hersey, R.F. Kefford, R.A. Scolyer, and G.V. Long Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment J. Immunol. 192 2014 2505 2513
62. G.H. Windbichler, H. Hausmaninger, W. Stummvoll, A.H. Graf, C. Kainz, and J. Lahodny Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial Br. J. Cancer 82 2000 1138 1144
63. Z. Yu, T.G. Pestell, M.P. Lisanti, and R.G. Pestell Cancer stem cells Int. J. Biochem. Cell Biol. 44 2012 2144 2151
64. W. Zhang, H. Chen, D.L. Liu, H. Li, J. Luo, J.H. Zhang, Y. Li, K.J. Chen, H.F. Tong, and S.Z. Lin Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets Int. J. Oncol. 42 2013 1189 1196